Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,084 INR | -0.92% |
|
+1.42% | +5.35% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.02 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.35% | 2B | C- | ||
+18.69% | 84.15B | C+ | ||
-25.20% | 74.14B | B- | ||
+1.62% | 26.92B | C+ | ||
-10.46% | 17.15B | B | ||
-0.68% | 16.83B | A- | ||
-0.73% | 15.21B | A- | ||
+72.88% | 13.3B | C- | ||
+76.04% | 12.99B | C+ | ||
-25.79% | 12.79B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KIMS Stock
- KIMS Stock
- Ratings Krishna Institute of Medical Sciences Limited